• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Fractyl Health Inc.

    11/14/24 4:30:50 PM ET
    $GUTS
    Get the next $GUTS alert in real time by email
    SC 13G 1 d891783dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    Fractyl Health, Inc.

    (Name of Issuer)

    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)

    35168W103

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☒

    Rule 13d-1(b)

     

    ☐

    Rule 13d-1(c)

     

    ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 35168W103      

     

     1   

     NAMES OF REPORTING PERSONS

     

     Maverick Capital, Ltd.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Texas

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     4,248,492

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     4,248,492

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,248,492

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     8.9%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IA


    CUSIP No. 35168W103      

     

     1   

     NAMES OF REPORTING PERSONS

     

     Maverick Capital Management, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Texas

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     4,248,492

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     4,248,492

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,248,492

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     8.9%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     HC


    CUSIP No. 35168W103      

     

     1   

     NAMES OF REPORTING PERSONS

     

     Lee S. Ainslie III

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     4,248,492

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     4,248,492

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,248,492

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     8.9%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN


    Item 1(a).

    Name of Issuer:

    Fractyl Health, Inc.

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    3 Van de Graaff Drive Suite 200

    Burlington, Massachusetts 01803

     

    Item 2(a).

    Names of Persons Filing:

    This Schedule 13G (the “Schedule 13G”) is being filed on behalf of each of the following persons (each, a “Reporting Person”):

    (i) Maverick Capital, Ltd.;

    (ii) Maverick Capital Management, LLC; and

    (iii) Lee S. Ainslie III (“Mr. Ainslie”).

    The Schedule 13G relates to the shares of Common Stock (as defined herein) held for the accounts of Maverick Capital, Ltd.’s clients.

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of (i) Maverick Capital, Ltd. and Maverick Capital Management, LLC is 1900 N. Pearl Street, 20th Floor, Dallas, Texas 75201, and (ii) Mr. Ainslie is 360 South Rosemary Ave., Suite 1440, West Palm Beach, Florida 33401.

     

    Item 2(c).

    Citizenship:

    (i) Maverick Capital, Ltd. is a Texas limited partnership;

    (ii) Maverick Capital Management, LLC is a Texas limited liability company; and

    (iii) Mr. Ainslie is a citizen of the United States.

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, par value $0.00001 per share (“Common Stock”)

     

    Item 2(e).

    CUSIP Number:

    35168W103


    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)   

    ☐   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

    (b)   

    ☐   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

    (c)   

    ☐   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

    (d)   

    ☐   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

    (e)   

    ☒   An investment advisor in accordance with §240.13d-1(b)(1)(ii)(E).

    (f)   

    ☐   An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

    (g)   

    ☒   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).

    (h)   

    ☐   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

    (i)   

    ☐   A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

    (j)   

    ☐   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

    (k)   

    ☐   Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    Item 4.

    Ownership.

    Ownership as of September 30, 2024 is incorporated by reference to items (5) – (9) and (11) of the cover page of the Reporting Person. The ownership percentages are based on 47,927,214 shares of Common Stock outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 14, 2024.

    Maverick Capital, Ltd. is an investment adviser registered under Section 203 of the Investment Advisers Act of 1940 and, as such, may be deemed to have beneficial ownership of the shares of Common Stock which are the subject of this filing through the investment discretion it exercises over its clients’ accounts. Maverick Capital Management, LLC is the General Partner of Maverick Capital, Ltd. Mr. Ainslie is the manager of Maverick Capital Management, LLC.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.


    Item 10.

    Certification.

    By signing below each of the Reporting Persons certifies that, to the best of such person’s knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: November 14, 2024

     

    MAVERICK CAPITAL, LTD.
    By:   Maverick Capital Management, LLC, its General Partner
    By:   Lee S. Ainslie III, Manager
    By:  

    /s/ Trevor Wiessmann

      Trevor Wiessmann
      Under Power of Attorney dated March 15, 2018
    MAVERICK CAPITAL MANAGEMENT, LLC
    By:   Lee S. Ainslie III, Manager
    By:  

    /s/ Trevor Wiessmann

      Trevor Wiessmann
      Under Power of Attorney dated March 15, 2018
    LEE S. AINSLIE III
    By:  

    /s/ Trevor Wiessmann

      Trevor Wiessmann
      Under Power of Attorney dated March 15, 2018


    EXHIBIT INDEX

     

    A.

    Joint Filing Agreement, dated November 14, 2024, by and among Maverick Capital, Ltd., Maverick Capital Management, LLC and Lee S. Ainslie III.

     

    B.

    Power of Attorney, Lee S. Ainslie III, dated March 15, 2018.

    Get the next $GUTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GUTS

    DatePrice TargetRatingAnalyst
    2/28/2024Outperform
    Evercore ISI
    2/27/2024$18.00Overweight
    Morgan Stanley
    2/27/2024$26.00Buy
    BofA Securities
    More analyst ratings

    $GUTS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes

      First-in-human study will evaluate safety, tolerability, and early efficacy of a one-time, pancreas-targeted smart GLP-1TM gene therapy for patients with inadequately controlled T2D and obesity Expect to dose first patients and report preliminary data in 2026, pending CTA authorization BURLINGTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company), a metabolic therapeutics company pioneering pattern-breaking treatments for obesity and type 2 diabetes (T2D), today announced that it has submitted the first module of its Clinical Trial Application (CTA) in Europe for RJVA-001, the Company's gene therapy candidate from its Rejuva platform. RJVA-001 is de

      5/19/25 7:00:00 AM ET
      $GUTS
    • Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates

      REVEAL-1 Cohort 3-month open-label data update expected in June 2025; early clinical signals reinforce Revita's potential to maintain weight loss after GLP-1 discontinuation in the real world REMAIN-1 Midpoint Cohort data expected in Q3 2025; first randomized data on post-GLP-1 weight maintenance REMAIN-1 Pivotal Cohort has completed enrollment ahead of schedule; 6-month primary endpoint data anticipated in H2 2026 Rejuva gene therapy platform advancing toward first-in-human studies; first CTA module submission for RJVA-001 expected in June 2025 Conference call today at 4:30 p.m. ET BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) ("the Company"),

      5/13/25 4:05:00 PM ET
      $GUTS
    • Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference

      BURLINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the first quarter 2025 and provide business updates on Tuesday, May 13, 2025, at 4:30 p.m. ET. A live webcast of the conference call can be accessed in the "Events" section of Fractyl Health's website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event. The Company also announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Off

      5/6/25 7:00:00 AM ET
      $GUTS

    $GUTS
    Financials

    Live finance-specific insights

    See more
    • Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates

      REVEAL-1 Cohort 3-month open-label data update expected in June 2025; early clinical signals reinforce Revita's potential to maintain weight loss after GLP-1 discontinuation in the real world REMAIN-1 Midpoint Cohort data expected in Q3 2025; first randomized data on post-GLP-1 weight maintenance REMAIN-1 Pivotal Cohort has completed enrollment ahead of schedule; 6-month primary endpoint data anticipated in H2 2026 Rejuva gene therapy platform advancing toward first-in-human studies; first CTA module submission for RJVA-001 expected in June 2025 Conference call today at 4:30 p.m. ET BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) ("the Company"),

      5/13/25 4:05:00 PM ET
      $GUTS
    • Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference

      BURLINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the first quarter 2025 and provide business updates on Tuesday, May 13, 2025, at 4:30 p.m. ET. A live webcast of the conference call can be accessed in the "Events" section of Fractyl Health's website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event. The Company also announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Off

      5/6/25 7:00:00 AM ET
      $GUTS
    • Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

      Strong patient and physician demand for pivotal REMAIN-1 study highlights urgent need for post-GLP-1 withdrawal weight maintenance solutions; midpoint data analysis anticipated in Q2 2025 and full study enrollment expected in summer 2025 Company plans to submit first Clinical Trial Application (CTA) module for RJVA-001 in type 2 diabetes to regulators in H1 2025, and if CTA is authorized, expects to report preliminary data in 2026 Conference call today at 4:30 p.m. ET BURLINGTON, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) ("the Company"), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 D

      3/3/25 4:05:00 PM ET
      $GUTS

    $GUTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Royan Ajay bought $22,980 worth of shares (17,901 units at $1.28) (SEC Form 4)

      4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

      3/18/25 7:57:09 PM ET
      $GUTS
    • Director Barnes Kelly Ann bought $40,210 worth of shares (31,000 units at $1.30) (SEC Form 4)

      4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

      3/18/25 4:50:44 PM ET
      $GUTS
    • Director Schulman Amy W bought $9,964 worth of shares (8,550 units at $1.17) (SEC Form 4)

      4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

      3/17/25 5:09:08 PM ET
      $GUTS

    $GUTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI initiated coverage on Fractyl Health

      Evercore ISI initiated coverage of Fractyl Health with a rating of Outperform

      2/28/24 8:22:09 AM ET
      $GUTS
    • Morgan Stanley initiated coverage on Fractyl Health with a new price target

      Morgan Stanley initiated coverage of Fractyl Health with a rating of Overweight and set a new price target of $18.00

      2/27/24 6:55:29 AM ET
      $GUTS
    • BofA Securities initiated coverage on Fractyl Health with a new price target

      BofA Securities initiated coverage of Fractyl Health with a rating of Buy and set a new price target of $26.00

      2/27/24 6:55:03 AM ET
      $GUTS

    $GUTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $GUTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form SC 13G filed by Fractyl Health Inc.

      SC 13G - FRACTYL HEALTH, INC. (0001572616) (Subject)

      11/14/24 4:30:50 PM ET
      $GUTS
    • SEC Form SC 13G filed by Fractyl Health Inc.

      SC 13G - FRACTYL HEALTH, INC. (0001572616) (Subject)

      11/13/24 5:17:27 PM ET
      $GUTS
    • SEC Form SC 13G filed by Fractyl Health Inc.

      SC 13G - Fractyl Health, Inc. (0001572616) (Subject)

      2/16/24 9:43:25 PM ET
      $GUTS
    • Amendment: SEC Form 4 filed by Director Conaway Samuel

      4/A - FRACTYL HEALTH, INC. (0001572616) (Issuer)

      3/18/25 8:18:31 PM ET
      $GUTS
    • Director Royan Ajay bought $22,980 worth of shares (17,901 units at $1.28) (SEC Form 4)

      4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

      3/18/25 7:57:09 PM ET
      $GUTS
    • Director Barnes Kelly Ann bought $40,210 worth of shares (31,000 units at $1.30) (SEC Form 4)

      4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

      3/18/25 4:50:44 PM ET
      $GUTS

    $GUTS
    SEC Filings

    See more
    • Fractyl Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)

      5/19/25 9:27:21 AM ET
      $GUTS
    • Fractyl Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)

      5/19/25 7:00:08 AM ET
      $GUTS
    • Fractyl Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)

      5/13/25 4:05:11 PM ET
      $GUTS

    $GUTS
    Leadership Updates

    Live Leadership Updates

    See more
    • Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

      BURLINGTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced the appointment of Adrian Kimber as Chief Commercial Officer. Mr. Kimber joins Fractyl with over two decades of experience in the biotechnology and medical devices sectors. Throughout his career, he has showcased a commendable history of introducing groundbreaking therapies to worldwide markets. Renowned for his adeptness in formulating go-to-market strategies, assembling and leading commercial teams, and implementing operational excellence, he

      4/2/24 8:00:00 AM ET
      $GUTS
    • Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials

      LEXINGTON, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) ("Fractyl Health" or the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of Type 2 Diabetes (T2D) and obesity, today announced the appointment of Samuel Conaway to its Board of Directors. Mr. Conaway's extensive background in the commercialization of medical technologies and leadership in new product launches will provide valuable insight and experience as Fractyl Health advances through pivotal clinical studies for T2D and weight loss maintenance and continues its ongoing pilot launch and real-world registry study of Revita in Germany. "Sam Conaway's

      2/20/24 8:38:00 AM ET
      $GUTS